RESEARCH TRIANGLE PARK, N.C., May 3, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that it will host a conference call on Friday, May 11, 2012 at 8:30 am ET to discuss first quarter 2012 financial results. The Company will report first quarter 2012 financial results after the close of the market on Thursday, May 10, 2012.
To participate in the live call, please dial (877) 670-9784 (U.S. and Canada) or (970) 315-0430 (international), five to ten minutes prior to the start of the call. A live audio webcast will also be available in the "Investors" section of the Tranzyme Pharma website, www.tranzyme.com.
A replay of the conference call will be available from May 11, 2012 at 11:30 am ET through May 18, 2012. Investors may listen to the replay by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), with the passcode 74990777. The webcast will also be archived for on-demand listening for 30 days at www.tranzyme.com.
About Tranzyme Pharma
Tranzyme Pharma is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 40 percent of people in the U.S. are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, currently there are a limited number of safe and effective treatment options. Tranzyme's oral ghrelin agonist, TZP-102, targets this significantly underserved market and is currently being evaluated in a Phase 2b trial enrolling patients with chronic diabetic gastroparesis. Top-line data from this trial are expected by the end of 2012. By leveraging its proprietary drug discovery technology, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical needs.
Further information about Tranzyme Pharma can be found on the Company's web site at www.tranzyme.com.